ARE PRESCRIPTION DRUG PRICES HIGH

被引:90
|
作者
VAGELOS, PR
机构
[1] Merck and Co., Inc., Rahway
关键词
D O I
10.1126/science.252.5009.1080
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The U.S. pharmaceutical industry has been criticized because its products are perceived to be too expensive, yet prescription medicines remain the least expensive form of therapy. At this time, we are experiencing a dramatic increase in the risks and costs of pharmaceutical research and development (R&D). An example may be seen in the R&D history of lovastatin. The U.S. pharmaceutical industry continues to lead the world in the discovery and development of important new medicines because it assumes greater financial risk and invests more of its sales dollar in R&D than virtually any other industry. Where such a risk is posed, there must continue to be the potential for profits. Pharmaceutical companies must set responsible prices, must keep price increases down, and must help improve access to important medicines.
引用
收藏
页码:1080 / 1084
页数:5
相关论文
共 50 条
  • [21] Availability and Variation of Publicly Reported Prescription Drug Prices
    Kullgren, Jeffrey T.
    Segel, Joel E.
    Peterson, Timothy A.
    Fendrick, A. Mark
    Singh, Simone
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (07): : 444 - +
  • [22] The effect of Canadian imports on prescription drug prices in the US
    Hamilton, Jonathan H.
    [J]. REGIONAL SCIENCE AND URBAN ECONOMICS, 2012, 42 (06) : 1003 - 1008
  • [23] Trends in Prescription Drug Launch Prices, 2008-2021
    Rome, Benjamin N.
    Egilman, Alexander C.
    Kesselheim, Aaron S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (21): : 2145 - 2147
  • [24] Caps on Capsules: Prescription for Lower Drug Prices in the United States
    Chasse, Christine
    [J]. FOOD AND DRUG LAW JOURNAL, 2020, 75 (02) : 280 - 310
  • [25] The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA
    Lindsay Allen
    [J]. Applied Health Economics and Health Policy, 2024, 22 : 5 - 7
  • [27] RETAIL DRUG PRICES - DISCRIMINATING PATIENT, PHARMACY, AND PRESCRIPTION VARIABLES
    HUNTER, RH
    BENNETT, JA
    HOLROYDE, J
    COLON, VF
    [J]. CONTEMPORARY PHARMACY PRACTICE, 1981, 4 (01) : 25 - 31
  • [28] Reducing Branded Prescription Drug Prices: A Review of Policy Options
    Alexander, G. Caleb
    Ballreich, Jeromie
    Socal, Mariana P.
    Karmarkar, Taruja
    Trujillo, Antonio
    Greene, Jeremy
    Sharfstein, Joshua
    Anderson, Gerard
    [J]. PHARMACOTHERAPY, 2017, 37 (11): : 1469 - 1478
  • [29] Policy Options to Lower Prescription Drug Prices in the United States
    Alexander, G. Caleb
    Ballreich, Jeromie
    Socal, Mariana P.
    Karmarkar, Taruja
    Trujillo, Antonio
    Green, Jeremy
    Sharfstein, Joshua
    Anderson, Gerard
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 625 - 626